Company profile
CervoMed Inc.
NASDAQ: CRVO · Healthcare · Biotechnology
#724 of 1,417 Healthcare companies by revenuebottom-quartile growth
EA Score
42DFH 35DQ 54GM 34SS 53
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, listing tenure · ↓ revenue growth (YoY), Piotroski F
Methodology →Revenue TTM
$322.6k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$27.0M
Employees
15
as of 2026-08-20
Market cap
$25.1M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$4.0M$4.0M2025
Net income-$27.0M-$27.0M2025
Operating income-$28.3M-$28.3M2025
Total assets$22.9M$22.9M2025
Liabilities$4.7M$4.7M2025
Equity$18.2M$18.2M2025
Revenue trend
FY2011 – FY2025 · USD
FY11
FY12
FY12
FY13
FY23
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is CervoMed Inc.’s revenue?
CervoMed Inc. booked $4.0M in FY2025 revenue, contracting 59% year over year — slower than 84% of Healthcare companies we track, at a -673.1% net margin.
Peers · Healthcare
Insight Molecular Diagnostics Inc.37DHemagen Diagnostics, Inc.——CG Oncology Inc.47DTenon Medical, Inc.35DNovaBridge Biosciences36DTarget Group Inc.46DNeighbors
Suffolk →Key facts
CEOJohn J. Alam
SectorHealthcare
IndustryBiotechnology
HeadquartersBoston, MA
ExchangeNASDAQ: CRVO
Employees15
IPO date2008-05-23
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.